- Home
- KZR vs PASG Comparison
KZR vs PASG Comparison
Compare KZR & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- PASG
- Stock Information
- Founded
- KZR 2015
- PASG 2017
- Country
- KZR United States
- PASG United States
- Employees
- KZR N/A
- PASG N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- PASG Health Care
- Exchange
- KZR Nasdaq
- PASG Nasdaq
- Market Cap
- KZR 29.7M
- PASG 27.6M
- IPO Year
- KZR 2018
- PASG 2020
- Fundamental
- Price
- KZR $6.19
- PASG $7.58
- Analyst Decision
- KZR Hold
- PASG Strong Buy
- Analyst Count
- KZR 4
- PASG 4
- Target Price
- KZR $6.00
- PASG $59.25
- AVG Volume (30 Days)
- KZR 456.4K
- PASG 39.4K
- Earning Date
- KZR 11-11-2025
- PASG 11-12-2025
- Dividend Yield
- KZR N/A
- PASG N/A
- EPS Growth
- KZR N/A
- PASG N/A
- EPS
- KZR N/A
- PASG N/A
- Revenue
- KZR N/A
- PASG N/A
- Revenue This Year
- KZR N/A
- PASG N/A
- Revenue Next Year
- KZR N/A
- PASG N/A
- P/E Ratio
- KZR N/A
- PASG N/A
- Revenue Growth
- KZR N/A
- PASG N/A
- 52 Week Low
- KZR $3.53
- PASG $5.12
- 52 Week High
- KZR $8.45
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- KZR 79.24
- PASG 44.60
- Support Level
- KZR $5.95
- PASG $8.02
- Resistance Level
- KZR $4.45
- PASG $8.99
- Average True Range (ATR)
- KZR 0.31
- PASG 0.62
- MACD
- KZR 0.24
- PASG -0.10
- Stochastic Oscillator
- KZR 92.67
- PASG 14.76
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.